Jiaowu Cao, Dingyao Hu, Jie Lv, Jin Chai, Yue Wang, Jie Chen et al. BTK Inhibitor Ibrutinib Reduces Bispecific Antibody‐Related CRS Without Undermining the Anti‐Tumor Efficacy. // Cancer Science. – 2026. – DOI: 10.1111/cas.70575. – URL: https://onlinelibrary.wiley.com/doi/10.1111/cas.70575?af=R
Jiaowu Cao, Dingyao Hu, Jie Lv, Jin Chai, Yue Wang, Jie Chen, Xiaoqiang Yan, Jun Zhu, & Hui Yu (2026). BTK Inhibitor Ibrutinib Reduces Bispecific Antibody‐Related CRS Without Undermining the Anti‐Tumor Efficacy. Cancer Science. https://doi.org/10.1111/cas.70575
Jiaowu Cao, et al. “BTK Inhibitor Ibrutinib Reduces Bispecific Antibody‐Related CRS Without Undermining the Anti‐Tumor Efficacy.” Cancer Science, 2026. doi:10.1111/cas.70575.
@article{Cao2026,
title = {BTK Inhibitor Ibrutinib Reduces Bispecific Antibody‐Related CRS Without Undermining the Anti‐Tumor Efficacy},
author = {Cao, Jiaowu and Hu, Dingyao and Lv, Jie and Chai, Jin and Wang, Yue and Chen, Jie and Yan, Xiaoqiang and Zhu, Jun and Yu, Hui},
journal = {Cancer Science},
year = {2026},
doi = {10.1111/cas.70575},
url = {https://onlinelibrary.wiley.com/doi/10.1111/cas.70575?af=R}
}